West Pharmaceutical Services Reports ThirdQuarter 2024 Financial Results

West Pharmaceutical Services Reports Third-Quarter 2024 Financial Results

West Pharmaceutical Services, Inc. (NYSE: WST) has announced its financial results for the third quarter of 2024, ending September 30, 2024.

Key Financial Metrics:

Despite a slight decline in revenue and EPS compared to the previous year, West Pharmaceutical Services exceeded analyst expectations, which anticipated an EPS of $1.50 and revenue of $709.62 million. The company's performance was bolstered by favorable currency movements.

Segment Revenue Performance:

The Proprietary Products segment saw a marginal decline, driven by lower sales in certain product lines, while the Contract-Manufactured Products segment experienced slight growth, primarily due to increased demand for self-injection devices.

Operational Highlights:

• Operating cash flow for the first nine months of 2024 was $463.3 million, a decrease of 13.8% from the previous year.
• The company repurchased 1,409,786 shares for $506.5 million under its share repurchase program.

Management Commentary:

Eric M. Green, President, CEO, and Chair of the Board, expressed satisfaction with the company's performance, highlighting the team's execution and strategic focus on improving patient lives through strong partnerships and collaboration with customers.

Dividends and Share Repurchase Program:

The Board of Directors declared a fourth-quarter 2024 dividend of $0.21 per share, a 5% increase from the previous quarters. The dividend is payable on November 20, 2024, to shareholders of record as of November 13, 2024.

Forward Guidance:

West Pharmaceutical Services raised its full-year 2024 guidance, expecting net sales between $2.875 billion and $2.905 billion, and adjusted EPS between $6.55 and $6.75, reflecting favorable currency impacts.

Stock Price Movement:

Following the earnings release, West Pharmaceutical Services' stock experienced a positive movement, with a 6.48% increase in its share price.

Overall, West Pharmaceutical Services demonstrated resilience in a challenging market environment, outperforming expectations and providing an optimistic outlook for the remainder of the fiscal year.